ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1639810
Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy: Impact on Chemotherapy Response Score and Prognosis in High-grade Serous Ovarian Carcinoma
Provisionally accepted
- 1Zhengzhou University, Zhengzhou, China
- 2Guangdong University of Technology, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study aimed to assess the therapeutic effects of neoadjuvant hyperthermic intraperitoneal chemotherapy (NHIPEC) combined with neoadjuvant chemotherapy (NACT) in patients with high-grade serous ovarian carcinoma.This study used a retrospective cohort design. A total of 120 patients with ovarian cancer who received NACT and underwent interval debulking surgery (IDS) at our hospital between 2016 and 2018 were enrolled in this study. Thereinto, 67 patients received the NHIPEC combined with the NACT regimen, and the remaining 53 patients received only NACT as the control. The degree of tumor burden reduction in patients treated with different regimens was evaluated using the chemotherapy response score (CRS), and patient survival data were analyzed.We found that the combination with NHIPEC is independently and positively correlated with a CRS reaching grade 3 (P=0.002), indicating that the combined treatment regimen has a significant advantage in improving the tumor response rate. Moreover, NHIPEC is an independent favorable prognostic factor for overall survival (OS) (P=0.032) and progressionfree survival (PFS) (P=0.029). Further analysis showed that the median OS and PFS of patients receiving the combined treatment regimen were extended to 40 and 16 months, respectively, compared with 34 and 15 months in the group receiving only NACT. In addition, the incidence of grade 3-4 adverse events is comparable between the two groups.This study supports the notion that the treatment regimen of NHIPEC combined with NACT can improve tumor response in advanced ovarian cancer compared with NACT alone.
Keywords: HGSOC, NHIPEC, NACT, CRS, prognosis
Received: 02 Jun 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Feng, Wang, Li, Zhang, Li, Ma, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaojie Feng, Zhengzhou University, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.